138 results about "Lost Weight" patented technology

Disclosed herein are methods for treating a subject with T2DM, obesity, or overweight with at least one weight related comorbidity using a glucagon-like peptide-1 (GLP-1) receptor non-peptide agonist (NPA) compound selected from Compound 1, Compound 1a, Compound 2, Compound 3, pharmaceutically acceptable salts thereof, and hydrates of the compounds and pharmaceutically acceptable salts, by oral administration to maintain body weight loss or reduced HbA1c levels resulting from a prior treatment with a GLP-1 RA. Also disclosed herein are uses of a GLP-1 receptor NPA compound for the manufacture of a medicament for treating a subject with T2DM, obesity, or overweight with at least one weight related comorbidity to maintain body weight loss or reduced HbA1c levels resulting from a prior treatment with a GLP-1 RA.

The invention provides an application of streptococcus salivarius in fatty liver, in particular to an application of streptococcus salivarius in preparation of a product, and the product is used for at least one of the following applications: (a) losing weight or reducing body fat; (b) improving the glucose tolerance of the patient; (c) increasing the sensitivity of the patient to insulin; (d) treating, relieving and preventing liver injury; (e) treating, relieving and preventing non-alcoholic steatohepatitis; (f) fat deposition caused by high-fat and high-cholesterol diet is reduced; (g) reducing blood fat; and / or (h) improving the level of at least one of the following indexes in the liver of the mammal: total cholesterol, triglyceride, low density lipoprotein-cholesterol and free fatty acid.

This disclosure provides methods for treating a condition or disease associated with weight gain that include administration of an apelin receptor agonist alone or in combination with a GLP-1 receptor agonist. Methods for increasing total weight loss in the subject relative to weight loss that would be caused by administration of a pre-determined amount of a GLP- 1 receptor agonist alone are also provided. In some embodiments, the method is for preserving, or maintaining muscle mass, muscle function, and / or muscle strength in a subject undergoing weight loss therapy. Also provided are method of treating diabetes or diabetic obesity. Also provided are method of treating heart failure with preserved ejection fraction. Also provided are pharmaceutical compositions, such as fixed dose combinations, that include an apelin receptor agonist and a GLP-1 receptor agonist. In some embodiments, the pharmaceutical composition is formulated for oral administration.

Methods and compositions promote weight loss in mammals, such as in humans and / or animals, such as, for example, pets. Specifically, the methods and compositions herein promote weight loss due to the production of appetite-suppressing gut hormones, increased metabolism, reduced fat and carbohydrate absorption, and reduced fat deposition through the synergistic combination of fibers and botanical extracts. Food products comprising the compositions herein provide a natural and effective means of controlling appetite and managing weight.

The present invention relates to a composition for preventing or treating inflammatory diseases, comprising a Lactobacillus sakei CVL-001 strain. The composition activates NOD2, which is an inflammation regulator, and exhibits the effects of inhibiting weight loss and improving clinical activity scores (disease activity index; DAI) in an animal model in which ulcerative colitis is induced, and thus the present invention can be effectively used in the prevention, treatment or alleviation of inflammatory diseases.

The present invention relates to pharmaceutical combinations for treating or preventing insulin resistance and associated disorders, in particular the use combinations comprising a 4-epimerase inhibitor and a GLP-1 receptor agonist for treating or preventing insulin resistance and associating disorders such as obesity and type-2 diabetes, supressing appetite and / or promoting weight loss.

This invention relates to isolated polypeptides that are analogs of human amylin. The disclosed amylin analog polypeptides have beneficial physicochemical properties relative to endogenous amylin, such as longer elimination half-lives (t1 / 2) and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed amylin analog polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed amylin analog polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as types 1 and 2 diabetes, and providing weight loss.

The present disclosure relates to a method of preventing or treating a disease or disorder in a subject in need thereof, wherein administration of a composition of the present disclosure is effective to result in an increase of energy expenditure in the subject. The present disclosure provides a method of reducing fat mass and / or improving glycemic control in a subject in need thereof. The present disclosure provides a method of promoting weight loss and weight maintenance. The present disclosure provides a method of maintaining lean mass. Compositions for use in the methods include a compound of formula (I), (II), or (III), or pharmaceutically acceptable salts thereof, or in combination with a compound selected from the group consisting of an ACC2 inhibitor and an incretin mimetic.

The invention relates to a composition with fat burning accelerating and weight losing effects and application thereof, and belongs to the technical field of traditional Chinese medicine. The technical problems that an existing classic prescription, namely the three-kernel decoction, is laggard in process and large in dosage are solved. The composition consists of the following traditional Chinese medicine extracts in parts by mass: 1-5 parts of a traditional Chinese medicine extract A, 4-7 parts of a traditional Chinese medicine extract B, 6-8 parts of a traditional Chinese medicine extract C and 3-9 parts of a traditional Chinese medicine extract D. According to the composition disclosed by the invention, the classical prescription of the Sanjing decoction is applied, the effective components are extracted and separated through modern science and technology to obtain an effective extract, the curative effect is exerted through a corresponding proportion, and pharmacodynamic research shows that the traditional Chinese medicine composition disclosed by the invention can achieve the effects of accelerating fat burning and losing weight through the effects of diminishing swelling, clearing damp, draining water and expelling toxin. And the related process is advanced, and the dose is not large.

This item is notebook paper used for recording neonatal jaundice and physiological weight loss.

Provided herein are methods of treating, preventing, or reducing conditions and / or side effects associated with anti-cancer agents (e.g., chemotherapeutic agents) via administration of a non-naturally occurring melanocortin analog prior to, during, and / or after administration of the anti-cancer agents. The methods reduce adverse effects associated with the anti-cancer agent, such as anorexia, weight loss, muscle mass loss, fat mass loss, wasting, reduced appetite, and loss of appetite, thereby enhancing tolerance of the anti-cancer agents and survival of the subject having cancer or having a disease or condition that is not cancer but is treated, reduced, or prevented by administration of an anti-cancer agent.

The invention discloses a functional solid beverage capable of reducing fat, losing weight and conditioning five highs. According to the functional solid beverage, dietary fibers such as fructo-oligosaccharide, inulin and the like are used for regulating intestinal flora, a white kidney bean extract is used for inhibiting the activity of alpha-amylase, L-carnitine is used for promoting fat transport, and medicinal and edible components such as ginseng, lotus leaves and the like are matched to realize multi-way metabolism regulation. The weight percentage of each component can be adjusted within a specified range so as to adapt to different physique requirements. Animal experiments prove that the total cholesterol (TC) of serum can be obviously reduced by 21.3-25.8% and the triglyceride (TG) can be obviously reduced by 28.9-34.2% after the traditional Chinese medicine is continuously taken for 4 weeks, and meanwhile, the insulin resistance index (HOMA-IR) can be improved to 16.5-20.3%.

The present invention relates to a composition for reducing appetite and / or promoting weight loss, the composition comprising, in a first compartment, a first composition comprising a hydrophilic polymer selected from polysaccharides, their derivatives and mixtures, a crosslinking compound, a foaming agent and a foam stabilizing agent, and, in a second compartment, separate from the first compartment, a second composition comprising citric acid. The invention also relates to methods of administering the composition according to the invention to a human or animal subject.

The name of the invention is compositions and methods for enhancing cancer radiotherapy. A nutritional supplement comprising fish oil and selenium has been determined to enhance radiotherapy of tumors in a synergistic manner. The co-therapy of such supplements and radiotherapy results in a significantly improved reduction in tumor volume in animal models and reduces the common side effects, such as weight loss, inflammation and gastrointestinal tract damage, relative to radiotherapy alone. It has also been found that this co-therapy can reduce the incidence of metastasis from a primary implant site and modulate the expression of genes associated with apoptosis in tumor cells. Formulations of such supplements with good tolerance and palatability are also provided.

Predicting a weight loss potential from gut microbiome data is described herein. In an example, a system accesses gut microbiome metagenomic sequence data for a subject and determines a measurement of one or more weight loss features from the gut microbiome metagenomic sequence data. The one or more weight loss features define a gut microbiome signature for weight loss response for the subject independent of a body mass index of the subject. The system determines a weight loss potential for the subject based on a comparison of the measurement of the subject to a plurality of reference measurements of the one or more weight loss features for a reference population showing variable weight loss responses. The system outputs the weight loss potential for the subject.

The present invention provides nutritional compositions for use in weight loss dietary interventions or in particular weight maintenance after dietary interventions, preferably after low calorie dietary interventions. The nutritional composition comprises one or more amino acids selected from the group consisting of proline, histidine, glycine and / or hydroxyproline, or a combination thereof, which can be used to assist in weight loss in obese subjects that are resistant to weight loss only by means of caloric limiting dietary intervention. In addition, the nutritional composition of the present invention may be used to help maintain the weight loss, particularly after dietary intervention.

The present invention relates to an immunogenic compound comprising an ApoB100 epitope, an immunogenic composition comprising the same, and uses thereof. The immunogenic compound can be used to prevent or treat diseases caused by increased ApoB100 levels or increased lipid levels by inducing an immune response to the ApoB100 epitope. The immunogenic compound has a complementary mechanism to GIP-1R agonist obesity treatments, so their combined or concurrent administration can enhance weight loss and improve side effects associated with long-term administration of GIP-1R agonist obesity treatments by improving weight loss plateaus, delaying the yo-yo effect, and improving lean body mass reduction.

The invention discloses a lipid-lowering and weight-losing composition with homology of medicine and food as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine compositions. The composition for reducing fat and losing weight comprises the following raw materials in parts by weight: 10-40 parts of lotus leaves, 20-50 parts of haws, 15-45 parts of poria cocos, 5-35 parts of dried orange peel, 60-130 parts of raspberries, 0-15 parts of fingered citron and 0-15 parts of kudzuvine roots. Compared with a model group, the fat-reducing and weight-losing composition disclosed by the invention has the advantages that the weight of a mouse can be reduced by 12%-15%, the serum total cholesterol level and the leptin level are reduced, the number of fat cells per unit area is increased, the liver adiposis symptom is obviously improved, the expression of heat production factors in epididymal fat and groin fat is up-regulated, and liver toxicity is avoided. The raw materials of the composition for reducing fat and losing weight are all traditional Chinese medicines with homology of medicine and food, so that the composition has no obvious damage to organisms and is safer; the fat-reducing and weight-losing composition can achieve a good weight-losing effect by compounding the raw materials.

The compositions and methods for improving or regulating GLP-1 levels, stimulating GLP-1 secretion, ameliorating metabolism including losing weight, managing glucose or insulin tolerance including stimulating insulin secretion, inhibiting glucagon secretion and reducing fasting glucose levels. The compositions comprise β-aminoisobutyric acid, a physiologically acceptable salt, polymer, ester, or 3-hydroxy-3-methylbutanoic acid, a physiologically acceptable salt, polymer, ester, or tributyrin or tributyrin derivative, or mixture thereof.

The invention belongs to the technical field of health-care food, and provides gel soft sweets for improving iron-deficiency anemia and a preparation method thereof, and the gel soft sweets comprise the following raw materials in parts by mass: 5-7 parts of an extract, 9-11 parts of compound gum and 2-4 parts of a sugar solution. According to the product, longan aril, angelica sinensis, fructus lycii, dried ginger, Chinese yam and honey-fried licorice root are used as functional components, carrageenan and agar are compounded to form a gel, erythritol is used as a sugar solution, and the functional gel soft sweets which have unique fragrance of traditional Chinese medicinal materials, are fine and smooth in texture and good in palatability and are easily accepted by the public are developed. Based on the characteristic that the medicinal and edible extract has a blood replenishing function, the candy has the effects of improving weight loss, hemoglobin content reduction and the like of people suffering from iron-deficiency anemia.

The present disclosure provides human inhibin subunit beta E (INHBE) gene-targeting double stranded oligonucleotides, compositions, and methods of using the same, either alone or in combination with additional therapeutics, for preventing and / or treating various INHBE-related disorders, including maintenance of weight loss achieved. In some embodiments, the provided double stranded oligonucleotides comprise certain chemistry modifications, e.g., stereospecific internucleotidic linkage modifications, and have unexpected advantageous properties.

The present disclosure provides a method for treating a condition or disease associated with weight gain, the method comprising co-administering an apelin receptor agonist and a GLP-1 receptor agonist. Also provided are methods of increasing overall weight loss in a subject relative to weight loss caused by administration of a predetermined amount of a GLP-1 receptor agonist alone. In some embodiments, the methods are used to maintain or maintain muscle mass, muscle function, and / or muscle strength in a subject undergoing a weight loss therapy.

To provide a T cell adaptor therapeutic agent and use thereof.SOLUTION: The T-cell adaptor is a T-cell bispecific antibody comprising a first binding domain that binds to BCMA on the target cell surface and a second binding domain that binds to CD3 on the T-cell surface. The bispecific antibody is well tolerated, can effectively block the binding of BCMA to its receptor APRIL, and has no adverse effects such as weight loss.SELECTED DRAWING: Figure 1

The present invention relates to pharmaceutical combinations comprising bupropion and trazodone and methods of using the same for affecting weight loss in subjects who may be obese, overweight or desire to lose undesirable or unwanted weight. The present invention also relates to pharmaceutical combinations comprising bupropion and trazodone and methods of using the same for inducing weight loss, effectuating weight management, improving a sexual disorder, and / or improving low or poor or a lack of a subjective state of well-being, self-esteem, and / or self-confidence in subjects who may be obese, overweight or desire to lose undesirable or unwanted weight or who want to maintain weight. The present invention also relates to pharmaceutical combinations comprising bupropion and trazodone and methods of using the same for weight loss and / or weight maintenance management.

An integrated weight management system comprising a biocompatible intraoral device and personalized software is disclosed. The device, configured for insertion into the user's mouth, creates a separation between the tongue and teeth causing the stomatognathic system, limiting hunger cues associated with food anticipation. Sensors coupled to the device detect its removal and insertion, enabling the system to track adherence to meal plans and weight loss progress. The software utilizes machine learning algorithms to generate personalized meal plans, food intake timing, nutrition education, and exercise routines based on user preferences, dietary restrictions, and weight loss goals. The system analyzes user data to provide progress reports, adjust meal plans, and send alerts to promote accountability and compliance. This comprehensive approach addresses both physiological and psychological aspects of weight management, offering a novel and effective solution for achieving and maintaining a healthy weight.

The present invention provides novel compounds that are peptide hormone analogs and are useful for treating disorders such as diabetes and obesity.The compounds of the general sequence listed herein have tailored profiles of potency at the GIP receptor.Regarding in vivo properties, administration of exemplary peptides of the present invention has been shown to result in improved weight loss in animal models.Preferred compounds achieve this without significantly reducing food intake.

Therapeutic combinations of capivasertib and venetoclax are described. This combination may be useful for treating B-cell malignancies. In some embodiments, reduced dosing (e.g., reduced frequency and / or reduced amount) of venetoclax can reduce or prevent effects, such as weight loss, that may be experienced with initial dosing regimens.

Methods and uses are presented in which a therapeutically effective unit dose of dodecanedioic acid (DDDA or DC12) is administered for an extended period of time to improve a subject's lipid metabolism. Preferred dosage units comprise no more than 5% of the subject's standard daily caloric intake and improvements in metabolism are associated with weight loss and / or reduction of visceral fat.

The invention provides a traditional Chinese medicine composition for diabetes and application, and relates to the technical field of traditional Chinese medicine pharmacy, the traditional Chinese medicine composition is composed of twelve traditional Chinese medicines of prepared rehmannia root, pulp of dogwood fruit, Chinese yam, rhizoma alismatis, poria cocos, cortex moutan, wolfberry fruit, semen cuscutae, rhizoma polygonati, radix polygonati officinalis, radices trichosanthis and mantis egg-case. Animal experiments show that the traditional Chinese medicine composition disclosed by the invention can be used for remarkably improving the weight loss trend of diabetic mice and improving the glucose metabolism disorder state by reducing fasting blood-glucose and 2h glucose tolerance; in addition, the traditional Chinese medicine composition can increase TP and GLB contents in serum of mice, reduce ALT and AST activity, effectively repair anabolism functions of livers of diabetic mice and inhibit inflammation and necrosis of hepatocytes, and a safe and efficient treatment scheme is provided for diabetes.

Provided are compositions comprising leptin and methods of using the same to support weight loss. Also provided are modified leptins, including recombinant leptins, and methods of making and using the same.